Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07396571

Predictive Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae

The goals of this observational study are to identify risk factors for ESBL-producing Enterobacterales and carbapenemase-producing Enterobacterales (CPE) colonization in oncohematological patients with severe neutropenia, and to develop and validate a predictive model of infection caused by ESBL-producing Enterobacterales and CPE in patients previously colonized by the same bacteria.

The main questions the study aims to answer are:

* What are the risk factors for ESBL-producing Enterobacterales and CPE colonization in patients with severe neutropenia? * Can a predictive model be developed to accurately predict infections in the colonized patients?

Study Design & Participants: Participants will be screened after receiving neutropenia-inducing treatment (e.g., chemotherapy, chimeric antigen receptor T-cell (CAR-T) therapy, or others). A baseline rectal swab will be collected to assess initial colonization status, followed by weekly swabs throughout the duration of neutropenia. Patients will be followed for 90 days from initial screening, during which the study team will record any infections, with an additional 30-day follow-up period. All hospitalization data will be recorded.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Hemato-oncologic Patients Agranulocytosis Colonization Cytopenia ESBL-producing Enterobacteriaceae Infections Enterobacteria Non Susceptible to Carbapenem Carrier Hematologic Diseases Hemic and Lymphatic Diseases Leukocyte Disorders Leukopenia Neutropenia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitario Torrecárdenas, Almería, Andalusia, Spain

Loading trial locations.

About this study

An exploratory metagenomics sub-study will be conducted within the study. Its goal is to describe the intestinal microbiome in patients and analyze any correlation between the microbiome and infection and mortality. For logistical reasons, this sub-study will be performed only on patients in the Seville area. This analysis will be performed via sequencing of the 16S ribosomal ribonucleic acid (rRNA) gene.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients admitted to Hematology departments with hematological diseases, including: myelodysplastic syndrome, acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, chronic lymphocytic leukemia, chronic myeloproliferative leukemias, lymphomas, or other hematological disorders.
  • Patients scheduled to receive treatment for their underlying hematological disease, including myeloablative/cytotoxic chemotherapy, conditioning chemotherapy for hematopoietic stem cell transplantation (autologous, allogeneic, or other types), lymphodepleting chemotherapy for CAR-T cell therapy, and/or other treatments expected to induce neutropenia.
  • Patients expected to develop neutropenia (neutrophil count < 0.5 \\times 10^9/L, or < 1.0 \\times 10^9/L when predicted to fall below 0.5 \\times 10^9/L within the next 48 hours) in the coming days.
  • Those who have signed the informed consent form.
  • Participation in another study is permitted, provided it is observational and does not influence the potential colonization status.

Exclusion criteria

  • Psychiatric disorder or inability to understand or follow the protocol instructions.
  • Terminally ill patients or those with an estimated life expectancy of less than 30 days.
  • Previous enrollment in the study.
  • Known prior colonization by ESBL-producing Enterobacteriaceae (ESBL-E) or carbapenemase-producing Enterobacteriaceae (CPE).
  • Physician's discretion: The patient's attending physician prefers not to include the patient in the study.

Treatment and study plan

Primary outcomes

  1. Number of patients colonized by ESBL-producing Enterobacterales and Carbapenem-resistant Enterobacterales (CRE) detected by rectal swab

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    A weekly control of colonizations status will be performed via rectal swabs, while the patient is hospitalized.

  2. Number of Neutropenic fever (NF) and/or clinically relevant infection events caused by ESBL-producing Enterobacterales and CPE

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    Due to the observational nature of the study, all cases of NF or infection will be registered in the electronic case report form (eCRF)

Secondary outcomes

  1. All cause mortality at 30 and 90 days

    Time frame: 90 day follow-up since inclusion

    Mortality at 30-days after inclusion and mortality at 90-days after inclusion

  2. In case of infection, mortality related to the infection at day 30 and/or recurrence of infection until day 90

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    For patients with an infection episode, mortality related to the infection and recurrence will be assessed at day 30 of the security follow-up

  3. Length of hospitalisation(s) (in days)

    Time frame: 90 days follow up since inclusion

    Total number of hospitalisation days during the 90 day follow-up.

  4. Data collection on antibiotic usage in Days of treatment (DOT)

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    Data collection on antibiotic usage in days of treatment

  5. Number of appropiate empirical and targeted treatment.

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    Data will be obtained from the participat's clinical history. Appropriate treatment is defined as confirmed activity in vitro of the treatment against the infectious agent.

  6. C. difficile infection

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    Rate of patients presenting confirmed Clostridioses difficile toxin presence

  7. Number of fungal infections caused by yeast or mold

    Time frame: 90 days follow-up. In case of infection a security follow-up of 30 days will be performed

    Proven, probable or possible fungal infection confirmed by growth of specimen in culture or fungal biomarkers.

Study contacts

Contact information is provided by the study sponsor or research team.

Zaira Palacios Baena R. MD/PhD

CONTACT

[email protected]

0034 609320301

Sponsors and collaborators

Lead sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Other

Registry information

Official study title

Development of a Predictive Infection Score in Patients With Hematological Malignancies Colonized by Multidrug-resistant Enterobacteriaceae

Acronym: SCREEN-IN

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 9, 2026
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.